Aspirin Use, Cardiovascular Events Among Adults With Hypertension, Controlled Systolic Blood Pressure

 

Free access to the full-text article http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.6952?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041222

Research Letter
Cardiology
April 12, 2022

Analysis of Aspirin Use and Cardiovascular Events and Mortality Among Adults With Hypertension and Controlled Systolic Blood Pressure

JAMA Netw Open. 2022;5(4):e226952. doi:10.1001/jamanetworkopen.2022.6952
Introduction

Aspirin use for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) has been questioned for having limited benefit in individuals with diabetes,1 neutral outcomes in individuals at low risk,2 and increased bleeding risk and mortality in healthy older individuals.3,4 Given the lack of specific updated evidence, we aimed to investigate whether aspirin use alongside guideline-directed blood pressure (BP) management targeting a systolic BP of less than 140 mm Hg is associated with decreased risk of a first cardiovascular event and improved survival among individuals with hypertension at increased risk of ASCVD.